Johnson & Johnson (JNJ) — closed signal from December 25, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 25, 2026.
Predicted vs. what happened
What happened
Reached its target in 33 days.
The thesis — published December 25, 2025
JNJ looks like a short-term trade for 0-3 months if markets calm. Recent positive headlines - inclusion on a high-yield list and FDA approval for Inlexzo - make people more willing to buy. Price indicators show it's been pushed low and could bounce, but overall momentum is still weak and investor sentiment doesn't match the company's fundamentals. Treat as a small, tactical trade with tight risk, not a long-term core holding.
Primary drivers
- FDA approval gives recent positive news and helps buying interest
- Healthcare stock may hold up better when markets get rocky
- Price has been pushed low, increasing chance of a short-term bounce
- Lower price swings let you set tighter stop-losses than high-risk stocks
How it played out
JNJ: target reached in 33 days
Lyra published JNJ at $207.78 on 2025-12-25 as a short-term trade for 0-3 months, with expected growth of 8%. The thesis pointed to FDA approval for Inlexzo, possible healthcare resilience if markets got rocky, a price that had been pushed low, and lower price swings that could support tighter risk control.
Inside the window, JNJ reached the $224.40 target in 33 days. It later peaked at $251.71 on 2026-03-02, a 21.1% gain. By 2026-03-25, it ended at $239.93. The thesis played out, and the target was exceeded.
What happened during the window
On January 21, 2026, Johnson & Johnson reported fourth-quarter net earnings of $5.12 billion and fourth-quarter revenue of $24.56 billion. The company also issued a 2026 forecast above Wall Street expectations, according to the same report.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.